Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: A systematic review and meta-analysis

Urologia Internationalis

Volumn 91, Issue 3, 2013, Pages 291-296

  Fang, Dong ^a   Li, Xue Song ^a   Xiong, Geng Yan ^a   Yao, Lin ^a   He, Zhi Song ^a   Zhou, Li Qun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Bladder cancer; Intravesical chemotherapy; Meta analysis; Nephroureterectomy; Upper urinary tract urothelial carcinoma

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ARABINOSIDE; EPIRUBICIN; MITOMYCIN; PIRARUBICIN;

ARTICLE; BLADDER IRRITATION; BLADDER TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CYSTALGIA; DRUG EFFECT; DRUG INSTILLATION; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MICTURITION DISORDER; NEPHROURETERECTOMY; PATIENT RISK; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLACTIC INTRAVESICAL CHEMOTHERAPY; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THERAPY EFFECT; TRANSITIONAL CELL CARCINOMA; URINARY URGENCY;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; NEPHRECTOMY; ODDS RATIO; RECURRENCE; RISK; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; URINARY TRACT; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84886376277     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000350508     Document Type: Article

References (29)

1. Munoz JJ, Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000; 164: 1523-1525.
2. Ploeg M, Aben KK, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
3. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
4. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG: Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-1233.
5. Cummings KB: Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1980; 7: 569-578.
6. Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y: Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005; 65: 279-283.
7. Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M: Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 2008; 71: 123-127.
8. Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W, Ficarra V: Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int 2008; 101: 1368-1374.
9. Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS: Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 2005; 96: 1031-1035.
10. Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C: Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int 2006; 98: 1181-1186.
11. Huang WW, Huang HY, Liao AC, Shiue YL, Tai HL, Lin CM, Wang YH, Lin CN, Shen KH, Li CF: Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol Int 2009; 59: 642-649.
12. Morioka M, Jo Y, Furukawa Y, Kinugawa K, Sone A, Matsuki T, Kobayashi T, Fujii T, Tanaka H: Prognostic factors for survival and bladder recurrence in transitional cell carcinoma of the upper urinary tract. Int J Urol 2001; 8: 366-373.
13. Miyake H, Hara I, Kamidono S, Eto H: Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol 2004; 172: 1127-1129.
14. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J: Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 2000; 164: 1183-1187.
15. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O: Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993; 342: 1087-1088.
16. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J, Hofstaedter F, Hartmann A: Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 2001; 20: 4910-4915.
17. Catto JW, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario DJ, Hamdy FC, Meuth M: Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 2006; 175: 2323-2330.
18. Takahashi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Kato T, Ogawa O, Habuchi T: Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J Urol 2001; 165: 672-677.
19. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF Jr, Fair WR, Oettgen HF: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 1987; 5: 441-449.
20. Sylvester RJ, Oosterlinck W, Witjes JA: The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review of the published results of randomized clinical trials. Eur Urol 2008; 53: 709-719.
21. O'Brien T, Ray E, Singh R, Coker B, Beard R: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: A prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011; 60: 703-710.
22. Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol 2010; 183: 56-61.
23. Tian J, Li C, Ma J, Xiao Z, Shou J, Xiao Z: A matched case-control study of postoperative intravesical chemotherapy for upper urinary tract tumor. J Clin Urol 2011; 26: 927-929.
24. Ito A, Satoh M, Shintaku I, Ishidoya S, Arai Y: Intravesical instillation of pirarubicin reduces the incidence of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: final result of a phase II prospective randomized trial. J Urol 2012; 187: 220-221.
25. Sakamoto N, Naito S, Kumazawa J, Ariyoshi A, Osada Y, Omoto T, Fujisawa Y, Morita I, Yamashita H: Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: A prospective randomized study. Int J Urol 2001; 8: 212-216.
26. Kudoh T, Motomura F, Saitoh F, Kogawa T, Suzuki T: Prophylactic intravesical BCG for bladder tumor after surgery of upper tract urothelial carcinoma (in Japanese). Nihon Hinyokika Gakkai Zasshi 1990; 81: 1857-1860.
27. Tari K, Satake I, Kojima S, Negishi T, Yoshida K, Nakame Y, Kanaoya F, Horiuchi S, Saito T, Owada F, et al: Prophylactic intravesical chemotherapy in bladder tumors after surgery of upper tract urothelial carcinoma (in Japanese). Hinyokika Kiyo 1987; 33: 852-856.
28. Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M: Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol 2009; 29: 130-136.
29. Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-2190; quiz 2435.